J&J adds satellite offices to innovation hub; U.K.'s Chronos raises $13M for ALS drug R&D;

@FierceBiotech: Alzheimers R&D: The biggest lottery in the industry, with a winning ticket worth an overnight fortune. Story | Follow @FierceBiotech

@JohnCFierce: So what are the 5 worst pharma media ops? Novartis certainly makes the list. Merck of course. Other suggestions? | Follow @JohnCFierce

@DamianFierce: The FDA's still wary of dapagliflozin, AstraZeneca and Bristol-Myers Squibb's once-rejected diabetes drug. More | Follow @DamianFierce

@EmilyMFierce: Nobel winner declares boycott of top science journals. Story via The Guardian | Follow @EmilyMFierce

> Oxford, U.K.-based Chronos Therapeutics has raised $13 million, which will fuel its work on a new drug for amyotrophic lateral sclerosis, or Lou Gehrig's disease, to Phase IIb. The University of Oxford and Vulpes Investment put up cash alongside new investors including Odey European Inc. and The Odey Swan Fund. Release

> Johnson & Johnson ($JNJ) is adding some spokes to its new innovation hub office in London. The pharma giant says it is opening satellite offices in Oxford, Cambridge, Edinburgh, Cardiff and Manchester as it looks to tap into the country's R&D network. Story

Medical Device News

@FierceMedDev: Edwards looks to a rocky 2014 as Medtronic looms. More | Follow @FierceMedDev

@MarkHFierce: $100M gets CareFusion a minority stake in an Israeli infusion pump maker--they're old friends as well. Story | Follow @MarkHFierce

@MichaelGFierce: New Hologic CEO aims for Dx revenue growth over sale option. Item | Follow @MichaelGFierce

@GalenMoore: Genetic testing: Invitae completes a $40 million series E financing. Release | Follow @GalenMoore

> St. Jude Medical will try again another day for a U.S. renal denervation study. More

> Disgraced founder, former exec team sentenced in PIP breast implant scandal. Story

Pharma News

@FiercePharma: Teva braces for a $550M hit from Copaxone generics. Story | Follow @FiercePharma

@EricPFierce: As this story says, Merck was getting heat on Fosamax litigation it is now settling. News | Follow @EricPFierce

@CarlyHFierce: Pfizer loses Supreme Court bid to squash $142M Neurontin verdict. More | Follow @CarlyHFierce

> Drugmakers, beware of tweets that trigger stock moves. Story

> Novo Nordisk is in hot water for delaying bad news on Tresiba. News

Pharma Manufacturing News

> Track-and-trace is here ... and now. Editor's corner

> FDA spanks a second Jubilant HollisterStier plant. More

> Alvogen makes a $250M biosimilars investment in Iceland. Story

> Biogen API plant gets dinged by the FDA. Article

> Hospira cuts costs by expanding drug and API production outside of the U.S. News

> Pharma Tech adds capacity as the CMO industry heats up. Report

> Feds close down importer that sold unapproved Botox and cancer drugs. Item

Biotech Research News

> Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. More

> GlaxoSmithKline initiates a global cancer consortium. Item

> Report: Global malaria R&D needs an $8.3B boost over next decade. Story

> Gene discovery could predict the responsiveness of antidepressants. Report

> International Stem Cell Corp. finds a new way to reprogram cells. News

> 1 in 100 cancers are associated with this gene mutation. Article

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.